Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3022855 |
Synonyms | |
Therapy Description |
LY3022855 (IMC-CS4) is a monoclonal antibody against colony stimulating factor 1 receptor (CSF1R), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells over expressing CSF1R (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3022855 | IMC-CS4 | CSF1R Antibody 5 | LY3022855 (IMC-CS4) is a monoclonal antibody against colony stimulating factor 1 receptor (CSF1R), which potentially induces antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells over expressing CSF1R (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02265536 | Phase I | LY3022855 | A Study of LY3022855 In Participants With Breast or Prostate Cancer | Completed | USA | 0 |
NCT01346358 | Phase I | LY3022855 | A Study of IMC-CS4 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |